

CORCEPT THERAPEUTICS INC  
Form 8-K  
November 19, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (date of earliest event reported): November 13, 2018**

**Corcept Therapeutics Incorporated**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**000-50679**  
**(Commission**

**File Number)**  
**149 Commonwealth Drive**

**77-0487658**  
**(I.R.S. Employer**

**Identification Number)**

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 8-K

**Menlo Park, CA 94025**

**(Address of principal executive offices, with zip code)**

**(650) 327-3270**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On November 13, 2018, Robert S. Fishman, M.D. informed Corcept Therapeutics Incorporated of his resignation as Chief Medical Officer, effective January 31, 2019 (the Termination Date ). It is expected that Dr. Fishman will continue to serve as Chief Medical Officer through the Termination Date to assist with the transition of his responsibilities.

**Forward-Looking Statements**

Statements in this Current Report, other than statements of historical fact, are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, are based on our current plans and expectations and are subject to risks and uncertainties that might cause actual results to differ materially from those such statements express or imply. These risks are set forth in our Securities and Exchange Commission ( SEC ) filings, which are available at our website and the SEC 's website. In this Current Report, forward looking statements include those concerning Dr. Fishman 's continued service through the Termination Date and assistance with the transition of his responsibilities. We disclaim any intention or duty to update forward-looking statements made in this Current Report.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CORCEPT THERAPEUTICS  
INCORPORATED**

By: /s/ G. Charles Robb  
Name: G. Charles Robb  
Title: Chief Financial Officer and  
Secretary

Date: November 19, 2018